ES3026709T3 - Cancer treatment using docetaxel by controlling peak plasma levels - Google Patents

Cancer treatment using docetaxel by controlling peak plasma levels Download PDF

Info

Publication number
ES3026709T3
ES3026709T3 ES19828724T ES19828724T ES3026709T3 ES 3026709 T3 ES3026709 T3 ES 3026709T3 ES 19828724 T ES19828724 T ES 19828724T ES 19828724 T ES19828724 T ES 19828724T ES 3026709 T3 ES3026709 T3 ES 3026709T3
Authority
ES
Spain
Prior art keywords
docetaxel
cancer
plasma concentrations
side effects
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19828724T
Other languages
English (en)
Spanish (es)
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Application granted granted Critical
Publication of ES3026709T3 publication Critical patent/ES3026709T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES19828724T 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels Active ES3026709T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215472 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Publications (1)

Publication Number Publication Date
ES3026709T3 true ES3026709T3 (en) 2025-06-12

Family

ID=64901394

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19828724T Active ES3026709T3 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Country Status (14)

Country Link
US (3) US20220079910A1 (enExample)
EP (1) EP3897610B1 (enExample)
JP (3) JP2022515249A (enExample)
KR (1) KR20220002860A (enExample)
CN (1) CN113543781A (enExample)
AU (2) AU2019410060A1 (enExample)
BR (1) BR112021012255A2 (enExample)
CA (1) CA3124316C (enExample)
CL (1) CL2021001638A1 (enExample)
ES (1) ES3026709T3 (enExample)
IL (1) IL284213A (enExample)
MX (2) MX2021007478A (enExample)
PE (1) PE20220250A1 (enExample)
WO (1) WO2020127606A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124319C (en) * 2018-12-21 2023-07-04 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
AU2008291930B2 (en) 2007-08-24 2014-04-17 Slotervaart Participaties Bv Compositions for the treatment of neoplastic diseases
EP2328555A2 (en) 2008-08-22 2011-06-08 Slotervaart Participaties BV Compositions for the treatment of neoplastic diseases
CA3124319C (en) * 2018-12-21 2023-07-04 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Also Published As

Publication number Publication date
BR112021012255A2 (pt) 2021-09-28
KR20220002860A (ko) 2022-01-07
PE20220250A1 (es) 2022-02-16
MX2025008270A (es) 2025-08-01
IL284213A (en) 2021-08-31
US20250312305A1 (en) 2025-10-09
CL2021001638A1 (es) 2022-04-22
US20220079910A1 (en) 2022-03-17
AU2019410060A1 (en) 2021-08-05
AU2023204682A1 (en) 2023-08-10
CN113543781A (zh) 2021-10-22
EP3897610C0 (en) 2025-04-16
WO2020127606A1 (en) 2020-06-25
JP2025094189A (ja) 2025-06-24
JP2022515249A (ja) 2022-02-17
US20220323399A1 (en) 2022-10-13
EP3897610A1 (en) 2021-10-27
CA3124316A1 (en) 2020-06-25
JP2023102787A (ja) 2023-07-25
EP3897610B1 (en) 2025-04-16
CA3124316C (en) 2023-07-04
MX2021007478A (es) 2021-10-13
US11571408B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
ES2734081T3 (es) Apilimod para el uso en el tratamiento de melanoma
JP2025094186A (ja) ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療
EP2638395A1 (en) Methods of treating cancer
KR102033305B1 (ko) 아스피린 및 다중 키나아제 억제제를 포함하는 항암제 내성 치료용 조성물
ES2256168T3 (es) Procedimiento para aumentar la biodisponibilidad y la penetracion en tejidos de azitromicina.
US20120101057A1 (en) Combined therapy of colorectal carcinoma
Baas et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer
US20240374628A1 (en) Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
CN118946350A (zh) 用于治疗紫杉烷耐药性患者的癌症的方法和组合物
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
JP2019511547A (ja) 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ
Mans et al. Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours.
EP3246029A1 (en) Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer